Reuters logo
8 months ago
BRIEF-ClinicalTrials.gov says Seattle Genetics' study of brentuximab vedotin combined with nivolumab suspends enrollment
January 5, 2017 / 4:44 PM / 8 months ago

BRIEF-ClinicalTrials.gov says Seattle Genetics' study of brentuximab vedotin combined with nivolumab suspends enrollment

Jan 5 (Reuters) - ClinicalTrials.gov :

* Seattle Genetics' study of brentuximab vedotin combined with nivolumab for relapsed or refractory hodgkin lymphoma suspends enrollment

* Seattle Genetics' enrollment for combo trial on hold pending protocol amendment to allow additional patients to be enrolled, treated Source text - bit.ly/2hWGLb2

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below